Baricitinib for Patients With Intracerebral Hemorrhage

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT06737705

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06737705
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06737705. Randomized; single masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2025-08-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Baricitinib for Patients With Intracerebral Hemorrhage
Acronym
BRIGHT
Condition
Intracerebral Hemorrhage
Intervention (Drug)
Baritinib
Lead sponsor
De-zhi Kang (class: other)
Collaborator
Fujian Medical University (class: other)
Collaborator
Tianjin Medical University General Hospital (class: other)

Record details

Record id
cardio:ct-nct06737705
Content hash
846b4f3b82afd1a11884dfb5fc4fcf0ea0cc7f6fbb184279aaeda35ddeab2794